How much did Wuhan Hvsen Biotechnology Co achieve in EBIT for the current year?
In the current year, Wuhan Hvsen Biotechnology Co has achieved an EBIT of 0 CNY.
Wuhan Hvsen Biotechnology Co EBIT 2024
Wuhan Hvsen Biotechnology Co EBIT
0 CNY
Ticker
300871.SZ
ISIN
CNE1000047H6
In 2024, Wuhan Hvsen Biotechnology Co's EBIT was 0 CNY, a 0% increase from the 13.73 M CNY EBIT recorded in the previous year.
The Wuhan Hvsen Biotechnology Co EBIT history
| YEAR | EBIT (undefined CNY) |
|---|---|
| 2026e | - |
| 2025e | - |
| 2024e | - |
| 2023 | 13.73 |
| 2022 | 65.78 |
| 2021 | 141.9 |
| 2020 | 171.5 |
| 2019 | 79.7 |
| 2018 | 82.4 |
| 2017 | 103.5 |
Wuhan Hvsen Biotechnology Co Revenue, EBIT, Net Income CNE1000047H6 ·
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Wuhan Hvsen Biotechnology Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Wuhan Hvsen Biotechnology Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Wuhan Hvsen Biotechnology Co’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Wuhan Hvsen Biotechnology Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Wuhan Hvsen Biotechnology Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Wuhan Hvsen Biotechnology Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Wuhan Hvsen Biotechnology Co’s growth potential.
Wuhan Hvsen Biotechnology Co Revenue, EBIT and net profit per share
| Date | Wuhan Hvsen Biotechnology Co Revenue | Wuhan Hvsen Biotechnology Co EBIT | Wuhan Hvsen Biotechnology Co Net Income |
|---|---|---|---|
| 2026e | 1.68 B undefined | 0 undefined | 169.83 M undefined |
| 2025e | 1.51 B undefined | 0 undefined | 171.48 M undefined |
| 2024e | 1.24 B undefined | 0 undefined | 98.38 M undefined |
| 2023 | 1.02 B undefined | 13.73 M undefined | 16.78 M undefined |
| 2022 | 1.02 B undefined | 65.78 M undefined | 52.71 M undefined |
| 2021 | 996.2 M undefined | 141.9 M undefined | 132.9 M undefined |
| 2020 | 777.5 M undefined | 171.5 M undefined | 150.2 M undefined |
| 2019 | 427.2 M undefined | 79.7 M undefined | 68.8 M undefined |
| 2018 | 421.9 M undefined | 82.4 M undefined | 71.4 M undefined |
| 2017 | 399.7 M undefined | 103.5 M undefined | 88.4 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2017 | 399.7 M CNY | 103.5 M CNY | 88.4 M CNY |
| 2018 | 421.9 M CNY | 82.4 M CNY | 71.4 M CNY |
| 2019 | 427.2 M CNY | 79.7 M CNY | 68.8 M CNY |
| 2020 | 777.5 M CNY | 171.5 M CNY | 150.2 M CNY |
| 2021 | 996.2 M CNY | 141.9 M CNY | 132.9 M CNY |
| 2022 | 1.02 B CNY | 65.78 M CNY | 52.71 M CNY |
| 2023 | 1.02 B CNY | 13.73 M CNY | 16.78 M CNY |
| 2024e | 1.24 B CNY | 0 CNY | 98.38 M CNY |
| 2025e | 1.51 B CNY | 0 CNY | 171.48 M CNY |
| 2026e | 1.68 B CNY | 0 CNY | 169.83 M CNY |
Wuhan Hvsen Biotechnology Co stock margins CNE1000047H6 ·
The Wuhan Hvsen Biotechnology Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Wuhan Hvsen Biotechnology Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Wuhan Hvsen Biotechnology Co.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Wuhan Hvsen Biotechnology Co's sales revenue. A higher gross margin percentage indicates that the Wuhan Hvsen Biotechnology Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Wuhan Hvsen Biotechnology Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Wuhan Hvsen Biotechnology Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Wuhan Hvsen Biotechnology Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Wuhan Hvsen Biotechnology Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Wuhan Hvsen Biotechnology Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Wuhan Hvsen Biotechnology Co Margin History
| Wuhan Hvsen Biotechnology Co Gross margin | Wuhan Hvsen Biotechnology Co Profit margin | Wuhan Hvsen Biotechnology Co EBIT margin | Wuhan Hvsen Biotechnology Co Profit margin |
|---|---|---|---|
| 2026e | 20.66 % | 0 % | 10.12 % |
| 2025e | 20.66 % | 0 % | 11.36 % |
| 2024e | 20.66 % | 0 % | 7.95 % |
| 2023 | 20.66 % | 1.35 % | 1.65 % |
| 2022 | 21.82 % | 6.43 % | 5.15 % |
| 2021 | 27.01 % | 14.24 % | 13.34 % |
| 2020 | 36.9 % | 22.06 % | 19.32 % |
| 2019 | 38.09 % | 18.66 % | 16.1 % |
| 2018 | 43.45 % | 19.53 % | 16.92 % |
| 2017 | 50.69 % | 25.89 % | 22.12 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2017 | 50.69 % | 25.89 % | 22.12 % |
| 2018 | 43.45 % | 19.53 % | 16.92 % |
| 2019 | 38.09 % | 18.66 % | 16.1 % |
| 2020 | 36.9 % | 22.06 % | 19.32 % |
| 2021 | 27.01 % | 14.24 % | 13.34 % |
| 2022 | 21.82 % | 6.43 % | 5.15 % |
| 2023 | 20.66 % | 1.35 % | 1.65 % |
| 2024e | 20.66 % | 0 % | 7.95 % |
| 2025e | 20.66 % | 0 % | 11.36 % |
| 2026e | 20.66 % | 0 % | 10.12 % |
Wuhan Hvsen Biotechnology Co Aktienanalyse
What does Wuhan Hvsen Biotechnology Co do?
Wuhan Hvsen Biotechnology Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Wuhan Hvsen Biotechnology Co's EBIT
Wuhan Hvsen Biotechnology Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Wuhan Hvsen Biotechnology Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Wuhan Hvsen Biotechnology Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Wuhan Hvsen Biotechnology Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Wuhan Hvsen Biotechnology Co Stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Wuhan Hvsen Biotechnology Co.
How has the EBIT of Wuhan Hvsen Biotechnology Co developed in recent years?
The EBIT of Wuhan Hvsen Biotechnology Co has increased by 0% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Wuhan Hvsen Biotechnology Co?
The EBIT of Wuhan Hvsen Biotechnology Co is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Wuhan Hvsen Biotechnology Co pay?
Over the past 12 months, Wuhan Hvsen Biotechnology Co paid a dividend of 0.3 CNY . This corresponds to a dividend yield of about 3.14 %. For the coming 12 months, Wuhan Hvsen Biotechnology Co is expected to pay a dividend of 0.3 CNY.
What is the dividend yield of Wuhan Hvsen Biotechnology Co?
The current dividend yield of Wuhan Hvsen Biotechnology Co is 3.14 %.
When does Wuhan Hvsen Biotechnology Co pay dividends?
Wuhan Hvsen Biotechnology Co pays a quarterly dividend. This is distributed in the months of June, May, July, June.
How secure is the dividend of Wuhan Hvsen Biotechnology Co?
Wuhan Hvsen Biotechnology Co paid dividends every year for the past 6 years.
What is the dividend of Wuhan Hvsen Biotechnology Co?
For the upcoming 12 months, dividends amounting to 0.3 CNY are expected. This corresponds to a dividend yield of 3.17 %.
In which sector is Wuhan Hvsen Biotechnology Co located?
Wuhan Hvsen Biotechnology Co is assigned to the 'Health' sector.
Wann musste ich die Aktien von Wuhan Hvsen Biotechnology Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Wuhan Hvsen Biotechnology Co from 5/29/2024 amounting to 0.27 CNY, you needed to have the stock in your portfolio before the ex-date on 5/29/2024.
When did Wuhan Hvsen Biotechnology Co pay the last dividend?
The last dividend was paid out on 5/29/2024.
What was the dividend of Wuhan Hvsen Biotechnology Co in the year 2023?
In the year 2023, Wuhan Hvsen Biotechnology Co distributed 0.331 CNY as dividends.
In which currency does Wuhan Hvsen Biotechnology Co pay out the dividend?
The dividends of Wuhan Hvsen Biotechnology Co are distributed in CNY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Wuhan Hvsen Biotechnology Co
Our stock analysis for Wuhan Hvsen Biotechnology Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Wuhan Hvsen Biotechnology Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Wuhan Hvsen Biotechnology Co Revenue
- Wuhan Hvsen Biotechnology Co Net Income
- Wuhan Hvsen Biotechnology Co P/E
- Wuhan Hvsen Biotechnology Co P/S
- Wuhan Hvsen Biotechnology Co EBIT
- Wuhan Hvsen Biotechnology Co Dividend
- Wuhan Hvsen Biotechnology Co Stocks
- Wuhan Hvsen Biotechnology Co Market capitalization
- Wuhan Hvsen Biotechnology Co Debt
- Wuhan Hvsen Biotechnology Co Liabilities
- Wuhan Hvsen Biotechnology Co Equity
- Wuhan Hvsen Biotechnology Co AAQS
- Wuhan Hvsen Biotechnology Co Employees
- Wuhan Hvsen Biotechnology Co ROE
- Wuhan Hvsen Biotechnology Co ROA
- Wuhan Hvsen Biotechnology Co ROCE